GANGLIONEUROBLASTOMA
Clinical trials for GANGLIONEUROBLASTOMA explained in plain language.
Never miss a new study
Get alerted when new GANGLIONEUROBLASTOMA trials appear
Sign up with your email to follow new studies for GANGLIONEUROBLASTOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on childhood cancer in new trial
Disease control Recruiting nowThis study tests a new treatment using specially designed immune cells (CAR-NK cells) that target two markers on neuroblastoma cells. It is for children and young adults aged 1 to 21 whose cancer has come back or not responded to standard treatments. Participants first receive ch…
Matched conditions: GANGLIONEUROBLASTOMA
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated May 17, 2026 04:46 UTC
-
Proton beam aims to spare kids with neuroblastoma from harsh radiation side effects
Disease control Recruiting nowThis study tests proton beam radiation for children with neuroblastoma, a nerve cell cancer. Proton radiation targets the tumor more precisely than standard X-ray radiation, which may reduce damage to nearby healthy organs. Researchers will track side effects like heart, lung, an…
Matched conditions: GANGLIONEUROBLASTOMA
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Promising new therapy combo targets tough childhood cancer
Disease control Recruiting nowThis study tests whether adding a radioactive drug (131I-MIBG) or a targeted pill (lorlatinib) to standard intensive therapy helps children with high-risk neuroblastoma live longer without the cancer coming back. About 750 children and young adults (ages 1 to 30) with newly diagn…
Matched conditions: GANGLIONEUROBLASTOMA
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New hope for kids with aggressive nerve cancer: immune-boosting NK cell combo enters final trial phase
Disease control Recruiting nowThis study tests a new treatment for children with high-risk neuroblastoma that has not responded to standard therapy or has come back. The approach combines chemotherapy, immunotherapy, and the patient's own natural killer (NK) cells to help the immune system fight the cancer mo…
Matched conditions: GANGLIONEUROBLASTOMA
Phase: PHASE3 • Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology • Aim: Disease control
Last updated Apr 26, 2026 19:37 UTC